Results 21 to 30 of about 2,891 (162)

miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer

Pharmaceuticals, 2021
Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Here, we pursued a combinatorial therapeutic approach to enhance the activity of selinexor, the first-in-class XPO1 inhibitor, by miR-34a ectopic expression ...
Silvia Martini, Valentina Zuco, Monica Tortoreto, Stefano Percio, Elisa Campi, Rihan El Bezawy, Valentina Doldi, Yosef Landesman, Marzia Pennati, Nadia Zaffaroni   +9 more
doaj   +1 more source

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma

Translational Oncology, 2017
Increased levels of the nuclear export protein, exportin 1 (XPO1), were demonstrated in multiple myeloma (MM) patients. Targeting XPO1 with selinexor (the selective inhibitor of nuclear export; SINE compound KPT-330) demonstrates broad antitumor activity
Barbara Muz, Feda Azab, Pilar de la Puente, Yosef Landesman, Abdel Kareem Azab   +4 more
doaj   +1 more source

Selinexor, a selective inhibitor of nuclear export, inhibits human neutrophil extracellular trap formation in vitro

Frontiers in Pharmacology, 2022
Neutrophils are central players in the innate immune system. To protect against invading pathogens, neutrophils can externalize chromatin to create neutrophil extracellular traps (NETs). While NETs are critical to host defense, they also have deleterious
Szilvia Baron, Szilvia Baron, Tami Rashal, Dmitry Vaisman, Dmitry Vaisman, Ronit Elhasid, Ronit Elhasid, Ronit Elhasid, Rachel Shukrun, Rachel Shukrun, Rachel Shukrun   +10 more
doaj   +1 more source

Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis

Hematology, 2023
Objectives Multiple myeloma (MM) remains an incurable disease despite advances in treatment options. Recently, selinexor has shown promising efficacy for relapsed/refractory multiple myeloma (RRMM), whereas its optimal timing and drug combination remain ...
Xinyuan Gu, Chunyan Sun, Juan Xu, Zhimei Lin, Li Zhang, Yuhuan Zheng   +5 more
doaj   +1 more source

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

Breast Cancer Research, 2017
Background Selinexor (KPT-330) is an oral agent that has been shown to inhibit the nuclear exporter XPO1. Given the pressing need for novel therapies for triple-negative breast cancer (TNBC), we sought to determine the antitumor effects of selinexor in ...
Natalia Paez Arango, Erkan Yuca, Ming Zhao, Kurt W. Evans, Stephen Scott, Charissa Kim, Ana Maria Gonzalez-Angulo, Filip Janku, Naoto T. Ueno, Debu Tripathy, Argun Akcakanat, Aung Naing, Funda Meric-Bernstam   +12 more
doaj   +1 more source

Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia

Scientific Reports, 2023
Despite recent relevant therapeutic progresses, chronic lymphocytic leukemia (CLL) remains an incurable disease. Selinexor, an oral inhibitor of the nuclear export protein XPO1, is active as single agent in different hematologic malignancies, including ...
Candida Vitale, Valentina Griggio, Maria Todaro, Chiara Riganti, Rebecca Jones, Elia Boccellato, Francesca Perutelli, Francesca Arruga, Tiziana Vaisitti, Dimitar G. Efremov, Silvia Deaglio, Yosef Landesman, Benedetto Bruno, Marta Coscia   +13 more
doaj   +1 more source

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts

Translational Oncology, 2021
Gain-of-function Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations occur in 25% of lung adenocarcinomas, and these tumors are challenging to treat.
Joshua C. Rosen, Jessica Weiss, Nhu-An Pham, Quan Li, Sebastiao N. Martins-Filho, Yuhui Wang, Ming-Sound Tsao, Nadeem Moghal   +7 more
doaj   +1 more source

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma

Journal of Translational Medicine, 2023
Background Extramedullary disease usually implies a dismal outcome in relapsed/refractory multiple myeloma patients, and requires novel treatment approaches.
Di Wang, Haiying Fu, Yimei Que, Haitao Ruan, Menglei Xu, Xiaolu Long, Qiuxia Yu, Chunhui Li, Zhe Li, Songbai Cai, Wei Chen, Cong Sun, Guang Hu, Shuai Wang, Donggou He, Jianming Mei, Wen Wang, Chunrui Li   +17 more
doaj   +1 more source

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma

Experimental Hematology & Oncology, 2023
Leiomyosarcoma (LMS) is a rare soft tissue sarcoma (STS) that begins in smooth muscle tissue and most often initiates in the abdomen or uterus. Compared with other uterine cancers, uterine LMS (ULMS) is an aggressive tumor with poor prognosis and a high ...
Sonam Mittal, Ishaque Pulikkal Kadamberi, Hua Chang, Feng Wang, Sudhir Kumar, Shirng-Wern Tsaih, Christopher J. Walker, Pradeep Chaluvally-Raghavan, John Charlson, Yosef Landesman, Sunila Pradeep   +10 more
doaj   +1 more source

Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation

Journal of Experimental & Clinical Cancer Research, 2021
Background Dedifferentiated liposarcoma (DDLPS), a tumor that lacks effective treatment strategies and is associated with poor outcomes, expresses amplified MDM2 in the presence of wild-type p53.
Valentina Zuco, Sandro Pasquali, Monica Tortoreto, Silvia Brich, Stefano Percio, Gian Paolo Dagrada, Chiara Colombo, Roberta Sanfilippo, Calogero Lauricella, Mrinal Gounder, Rihan El Bezawy, Marta Barisella, Angelo Paolo Dei Tos, Paolo Giovanni Casali, Alessandro Gronchi, Silvia Stacchiotti, Nadia Zaffaroni   +16 more
doaj   +1 more source